Streetbeat News

ASND

Ascendis Pharma A/S

https://ascendispharma.com

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

127.40

Mkt cap

7.1B

Volume

382K

High

127.99

P/E Ratio

-13.18

52-wk high

161.00

Low

124.11

Div yield

N/A

52-wk low

86.55

Specialised Therapeutics Asia has signed an exclusive agreement with Ascendis Pharma to distribute and commercialize three endocrinology therapies in Australia and select South-East Asia countries. The therapies include SKYTROFA for paediatric growth hormone deficiency, YORVIPA for hypoparathyroidism, and TransCon CNP for achondroplasia. The agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam. Two of the products are already internationally approved.

Portfolio Pulse from Charles Gross

January 07, 2024 | 7:34 pm

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a price target of $152.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:27 pm

Wedbush analyst Andreas Argyrides has maintained an Outperform rating on Ascendis Pharma (NASDAQ:ASND) and increased the price target from $200 to $202.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 1:58 pm

Jefferies analyst Kelly Shi has initiated coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and set a price target of $150 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 11:37 am

Ascendis Pharma A/S (NASDAQ:ASND) reported positive Phase 3 trial results for TransCon hGH, showing superiority over placebo and comparable effects to daily hGH in treating adult growth hormone deficiency. The trial met its primary and key secondary efficacy endpoints, and the treatment was well tolerated with no discontinuations. Ascendis plans to submit a supplemental Biologics License Application to the FDA next year. ASND shares rose 1.15% to $122.28.

Portfolio Pulse from Vandana Singh

December 19, 2023 | 7:31 pm

Wells Fargo analyst Derek Archila has reaffirmed an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and increased the price target from $137 to $149. This adjustment reflects a positive outlook on the company's stock, suggesting potential upside from its current trading level.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:23 pm

Ascendis Pharma A/S announced that the FDA has accepted for review the resubmitted NDA for TransCon PTH for treating adult hypoparathyroidism, with a PDUFA goal date of May 14, 2024.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:46 pm

Ascendis Pharma's stock is trading higher following the announcement of an exclusive license agreement with Teijin Limited for the Japan rights to its rare disease drugs.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 5:27 pm

Ascendis Pharma A/S has signed an exclusive license agreement with Teijin Limited, granting Teijin the rights to develop and commercialize Ascendis's endocrinology rare disease drugs in Japan. The deal is worth $70 million upfront, with the potential for up to $175 million in milestone payments, plus royalties on sales.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 9:35 am

Ascendis Pharma has received approval from the European Commission for YORVIPATH, a treatment for adults with chronic hypoparathyroidism. This marks a significant milestone for the company as it expands its product offerings in the European market.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.